Share Name Share Symbol Market Type Share ISIN Share Description
GlaxoSmithKline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.50p -0.55% 1,550.00p 1,554.50p 1,555.00p 1,558.00p 1,544.00p 1,556.00p 10,692,356.00 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,889.0 1,939.0 18.8 82.4 76,111.11

GlaxoSmithKline PLC Director/PDMR Shareholding

15/03/2017 5:07pm

UK Regulatory (RNS & others)


GlaxoSmithKline (LSE:GSK)
Historical Stock Chart

2 Months : From Mar 2017 to Apr 2017

Click Here for more GlaxoSmithKline Charts.

TIDMGSK

RNS Number : 6058Z

GlaxoSmithKline PLC

15 March 2017

GlaxoSmithKline plc (the 'Company')

Conditional Share Awards

As previously announced, on 15 February 2017 the Company granted conditional awards to certain Executive Directors and Persons Discharging Managerial Responsibilities ('PDMR'). This announcement relates to a PDMR who elected to participate in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan ('DABP') in respect of his bonus on a post-tax basis. The awards have been granted in accordance with the rules of the DABP which was approved by shareholders on 20 May 2009.

Participants are required to defer 25% of any bonus earned into Ordinary Shares or ADSs and may be eligible to choose to invest up to an additional 25% (i.e. up to a maximum of 50%) pre-tax (Deferred Bonus Award) and/or post-tax (Co-investment shares).

The Company will match the Deferred Bonus Award or Co-investment shares up to one-for-one depending on the achievement of performance targets (Matching Award). Details of the performance measures will be confirmed later in the year following shareholder approval of the Remuneration Policy at the Company's Annual General Meeting.

The performance period for the awards is the three financial years from 1 January 2017 to 31 December 2019.

The awards of deferred, co-investment and matching shares have been granted as conditional awards over ADSs for US pre-tax participants and as nil-cost options over Ordinary Shares for all other participants.

The vesting date for these conditional awards will be the later of the date, following the end of the three year performance period, on which the Remuneration Committee determines the extent to which the performance measures have been achieved, the third anniversary of the Award Date or such other later date as determined by the Remuneration Committee.

The amounts shown below are the maximum amounts payable (exclusive of dividend reinvestment during the performance period). The actual pay-out will be determined by performance over the period. Progress against targets will be reported in the Company's Annual Report yearly.

Transaction notification

 
 1.    Details of PDMR/person closely associated with them ('PCA') 
====  ============================================================================================== 
 a)    Name                                   Mr B McNamara 
====  ======================================  ====================================================== 
 b)    Position/status                        CEO, Consumer Healthcare 
====  ======================================  ====================================================== 
 c)    Initial notification/                  Initial Notification 
        amendment 
====  ======================================  ====================================================== 
 2.    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
====  ============================================================================================== 
 a)    Name                                   GlaxoSmithKline plc 
====  ======================================  ====================================================== 
 b)    LEI                                    5493000HZTVUYLO1D793 
====  ======================================  ====================================================== 
 3.    Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transaction(s) 
        has been conducted 
====  ============================================================================================== 
 a)    Description of                          American Depositary Shares ('ADSs') 
        the financial 
        instrument                              ISIN: US37733W1053 
====  ======================================  ====================================================== 
 b)    Nature of the 
        transaction                               1) Acquisition of post-tax Co-investment 
                                                  ADSs (under the GlaxoSmithKline 2009 Deferred 
                                                  Annual Bonus Plan). 
                                                  2) Acquisition of a matching award conditional 
                                                  award of ADSs (under the GlaxoSmithKline 
                                                  2009 Deferred Annual Bonus Plan) subject 
                                                  to performance measures. 
====  ======================================  ====================================================== 
 c)    Price(s) and volume(s)                  Price(s)                   Volume(s) 
====  ======================================  =========================  ========================= 
                                               $41.61                     2,087 
 ===========================================  =========================  ========================= 
                                               $41.61                     2,087 
                                              =========================  ========================= 
 
 d)    Aggregated information 
==== 
       Aggregated volume 
        Price                                 4,174 
                                               $41.61 
 ===========================================  ====================================================== 
 e)    Date of the transaction                2017-03-14 
====  ======================================  ====================================================== 
 f)    Place of the transaction               New York Stock Exchange (XNYS) 
====  ======================================  ====================================================== 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDELFFDXFBBBE

(END) Dow Jones Newswires

March 15, 2017 13:07 ET (17:07 GMT)

1 Year GlaxoSmithKline Chart

1 Year GlaxoSmithKline Chart

1 Month GlaxoSmithKline Chart

1 Month GlaxoSmithKline Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:gb D:20170430 01:21:22